Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68609 | 0.77 | SMN1; SMN2 (0.50) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL3262883 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL29141671 | 0.70 | MAOB (0.31) | CA2 | |
| SCHEMBL30303131 | 0.70 | — | — | |
| SCHEMBL2884635 | 0.69 | CA2 (0.59) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL7778678 | 0.68 | CA2 (0.40) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL2818988 | 0.68 | CA2 (0.36) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL7066153 | 0.67 | EPHX1 (0.63) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL15289984 | 0.67 | APLNR (0.42) | CA2POLBMEN1KMT2ACA12 | |
| SCHEMBL28342996 | 0.67 | ALDH1A1 (0.43) | CA2ALDH1A1POLBSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1308452-B1 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2008-03-19 | — | — | EP | disclosed |
| US-7282581-B2 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2007-10-16 | — | — | US | disclosed |
| US-20030118999-A1 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2003-06-26 | — | — | US | disclosed |
| EP-1308452-A2 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118999-A1 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | PCNA, DUT, POLL | CA2 1502/4885ALDH1A1 1108/4885POLB 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.